Sanofi and AstraZeneca Win FDA Approval for BEYFORTUS® Manufacturing Line to Protect Babies

Sep 16, 2024, 05:00 PM

Sanofi and AstraZeneca have received approval from the U.S. Food and Drug Administration (FDA) for a manufacturing line dedicated to their preventive respiratory syncytial virus (RSV) therapy. The approval allows Sanofi to begin shipping BEYFORTUS® in the United States, aimed at protecting babies against RSV disease. This development marks a significant step for both companies in their efforts to combat RSV.